Effects of ambroxol on Candida albicans growth and biofilm formation

Mycoses

Volumn 57, Issue 4, 2014, Pages 228-232

  Rene, Hernandez Delgadillo ^a   José, Martínez Sanmiguel Juan ^a   Isela, Sánchez Nájera Rosa ^a   Claudio, Cabral Romero ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Ambroxol; Antibiofilm; Antifungal agent; Antimicrobial resistance; Candida albicans; Mucolytic

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMBROXOL; ANTIFUNGAL AGENT; MUCOLYTIC AGENT; TERBINAFINE;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL VIABILITY; DRUG EFFECT; DRUG SCREENING; FLUORESCENCE MICROSCOPY; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; THRUSH;

CANDIDA ALBICANS;

AMBROXOL; ANTIBIOFILM; ANTIFUNGAL AGENT; ANTIMICROBIAL RESISTANCE; CANDIDA ALBICANS; MUCOLYTIC;

AMBROXOL; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, FLUORESCENCE; STAINING AND LABELING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84895779743     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12147     Document Type: Article

References (22)

1. Falagas ME, Fragoulis KN, Karydis I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE 2006; 1: e11.
2. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120: 1407-14.
3. Sasse C, Dunkel N, Schafer T et al. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol Microbiol 2012; 86: 539-56.
4. Reyes A, Reyes AC. Studies on Candida albicans infection in Filipino children. II. Prevalence of oral moniliasis. Acta Med Philipp 1956; 13: 151-5.
5. Costerton JW. Overview of microbial biofilms. J Ind Microbiol 1995; 15: 137-40.
6. Roberts AP, Mullany P. Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance. Expert Rev Anti Infect Ther 2010; 8: 1441-50.
7. Benakanakere M, Kinane DF. Innate cellular responses to the periodontal biofilm. Front Oral Biol 2012; 15: 41-55.
8. Fortun J. Antifungal therapy update: new drugs and medical uses. Enferm Infecc Microbiol Clin 2011; 29(Suppl. 5): 38-44.
9. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration 1987; 51(Suppl. 1): 37-41.
10. Heath MF, Jacobson W. The inhibition of lysosomal phospholipase A from rabbit lung by ambroxol and its consequences for pulmonary surfactant. Lung 1985; 163: 337-44.
11. Gillissen A, Scharling B, Jaworska M, Bartling A, Rasche K, Schultze-Werninghaus G. Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Res Exp Med (Berl) 1997; 196: 389-98.
12. Li F, Yu J, Yang H, Wan Z, Bai D. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol 2008; 57: 1-7.
13. Pfeifer S, Ziseel G, Kienast K, Muller-Quernheim J. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res 1997; 2: 129-32.
14. Gibbs BF, Schmutzler W, Vollrath IB et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res 1999; 48: 86-93.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
16. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 1997; 69: 581-93.
17. Yue H, Eastman PS, Wang BB. An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression. Nucleic Acids Res 2001; 29: E41-1.
18. Frey T. Nucleic acid dyes for detection of apoptosis in live cells. Cytometry 1995; 21: 265-74.
19. Lopez-Amoros R, Castel S, Comas-Riu J, Vives-Rego J. Assessment of E. coli and Salmonella viability and starvation by confocal laser microscopy and flow cytometry using rhodamine 123, DiBAC4(3), propidium iodide, and CTC. Cytometry 1997; 29: 298-305.
20. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48(Suppl. 1): 5-16.
21. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007; 52: 859-65.
22. Pulcrano G, Panellis D, De Domenico D, Rossano F, Catania MR. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm. FEMS Yeast Res 2012; 12: 430-8.